Cesca Therapeutics’ (KOOL) CEO Chris Xu on Q2 2018 Results – Earnings Call Transcript – Seeking Alpha
|
Cesca Therapeutics' (KOOL) CEO Chris Xu on Q2 2018 Results – Earnings Call Transcript
Seeking Alpha CAR–T cell based drugs are among the most advanced cancer therapies in the immuno-oncology field that target both hematopoietic cancers and solid tumors. CAR–T cell based immunotherapeutics have become the next pillar of cancer treatment, following … |
